
Molecular Pathology Laboratory Network, Inc. Selects HALO AP® to Deliver Comprehensive Reference Laboratory Services and Biopharma Laboratory Support
Indica Labs announced today that Molecular Pathology Laboratory Network, Inc. (MPLN),...
Molecular Pathology Laboratory Network (MPLN) is a leader in laboratory medicine, hematopathology, solid tumor oncology, immunology, and women’s health. Since our inception in 1989, we have pioneered the application of molecular pathology techniques in diagnostic and clinical research applications.
Advanced molecular profiling and precise biomarker studies drive targeted therapies in solid tumors, enhancing personalized treatment strategies for cancers including NSCLC, head and neck, prostate, breast and ovarian cancers
Cutting-edge diagnostics and precise classification transform the management of blood cancers, offering tailored insights for effective treatment planning in conditions such as AML, MDS, CLL, and multiple myeloma
Expert analysis in GI pathology delivers accurate diagnostics for liver diseases, NASH, prostate cancer, ulcerative colitis and urological conditions, providing critical insights for effective patient management and treatment
Benefit from seamless access to digital slides, enhanced cost-effectiveness and simplify slide retrieval. By embracing digital pathology, your clinical trials can achieve new heights of efficiency and success.
With over twenty years of invaluable experience and more than 400 completed studies in Phase I-IV clinical trials, we pride ourselves on our unparalleled expertise and knowledge in biopharma laboratory services.
We are committed to taking a unique and sophisticated approach to understanding disease mechanisms and effectively translating this into the unique requirements of each clinical trial.
MPLN has been at the forefront of specialty reference laboratory services for over thirty-five years, excelling in pathology, hematopathology, molecular diagnostics, infectious disease testing, and women’s health.
Our accredited reference laboratory, recognized by the College of American Pathologists (CAP), ISO 15189, and the New York State Department of Health (NYSDOH), is dedicated to delivering actionable, personalized results for better patient outcomes.
OUR FOCUS is bringing innovative technology to patient care. Molecular Pathology Laboratory Network (MPLN) is a leader in laboratory medicine, hematopathology, solid tumor oncology, immunology, and women’s health. Since our inception in 1989, we have pioneered the application of molecular pathology techniques in diagnostic and clinical research applications.
OUR APPROACH offers a unique understanding of the disease mechanism, integrating data from anatomic, cellular, and molecular investigations to provide physicians and clinical research teams with actionable information for patient monitoring and treatment decisions.
OUR COMMITMENT is that our CAP/CLIA & ISO 15189 accredited Global Laboratory Network will deliver high-quality data, maintain exceptional customer service, and provide project management and data management services, making us the ideal partner to support clinical patient management and advance your new therapeutic and IVD/CDx medical device projects.
Indica Labs announced today that Molecular Pathology Laboratory Network, Inc. (MPLN),...
Effective data management is crucial in the fast-paced world of clinical trials. At MPLN, our journe...
This multicenter analysis examines the genetic and clinical characteristics of individuals with a 47...
The realm of clinical trials is continuously evolving, with digital pathology emerging as a transfor...
Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced that Molecular Pathology L...
Unusual Acute Promyelocytic Leukemia, reflexed for FISH analysis; t(15;17) positive.
Our LIS Blue is a fast, easy-to-use, secure, and accessible laboratory information system developed using the latest web technology.
Beyond informing drug target discovery, validation, and clinical development, it uncovers critical genetic markers that drive disease progression and influence individual treatment responses. This empowers healthcare professionals to create more precise, tailored treatment plans, optimizing medical management based on each patient’s genetic profile.
DNA Solutions – WGS*, WGMS*, WES*, TSO-500 Comp, Pillar OncoReveal
RNA Solutions – Total RNA-Seq*, RNA exome*, mRNA*
Liquid Biopsy Solutions – TSO-500 ctDNA, PGDx elio™ plasma complete*
*Offered through fully accredited partner laboratories.
Our advanced technology enables simultaneous visualization of single or multiple biomarkers within the same tissue section, delivering comprehensive insights and precise diagnostics. With unmatched expertise and cutting-edge technology, our team supports you in understanding complex tissue microenvironments, aiding patient stratification and treatment response prediction.